The advances of DNA methylation in the liquid biopsy for the detection of lung cancer

被引：0

作者：

Chen, Yuxuan ^{[1
]}

Peng, Shuang ^{[1
]}

Wang, Cailian ^{[2
]}

机构：

[1] Southeast Univ, Sch Med, Nanjing, Jiangsu, Peoples R China

[2] Southeast Univ, Zhongda Hosp, Sch Med, Dept Oncol, Nanjing, Jiangsu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2025年 / 15卷

关键词：

liquid biopsy; DNA Methylation; lung cancer; biomarker; CtDNA; CELL-FREE DNA; BRONCHOALVEOLAR LAVAGE FLUID; GENE PROMOTER METHYLATION; PULMONARY NODULES; INDUCED TUMORIGENESIS; ABERRANT METHYLATION; BINDING PROTEINS; MARKER PANEL; PLASMA; RASSF1A;

D O I：

10.3389/fonc.2025.1547797

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the most common cancer in the world and the leading cause of cancer death. The absence of effective early detection is one of the major contributors to high mortality rate of lung cancer. Liquid biopsy has the potential to become as a new method for early detection of cancer due to its non-invasive nature, ease of access, and overall presentation of tumor. Liquid biopsy has garnered increasing attention for its role in early detection and tumor genome assessment through the examination of circulating tumor DNA (ctDNA) released by apoptotic or necrotic tumor cells. DNA methylation is a potential biomarker for liquid biopsy due to its early onset, cancer specificity, biological stability, and accessibility in bodily fluids. This review aims to present an overview of the process of DNA methylation, identify potential methylation gene targets, and explore the application of liquid biopsy in the detection of lung cancer.

引用

页数：9

共 95 条

[71]

Sakumi K, 1997, CANCER RES, V57, P2415

[72] The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14ARF, p16INK4a and RASSF1A in human lung cancer cell lines [J].

Sato, M ;

Horio, Y ;

Sekido, Y ;

Minna, JD ;

Shimokata, K ;

Hasegawa, Y .

ONCOGENE, 2002, 21 (31) :4822-4829

[73] DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients [J].

Schotten, Lea M. ;

Darwiche, Kaid ;

Seweryn, Michal ;

Yildiz, Vedat ;

Kneuertz, Peter J. ;

Eberhardt, Wilfried E. E. ;

Eisenmann, Stephan ;

Welter, Stefan ;

Sisson, Brianna E. ;

Pietrzak, Maciej ;

Wiesweg, Marcel ;

Ploenes, Till ;

Hager, Thomas ;

He, Kai ;

Freitag, Lutz ;

Aigner, Clemens ;

Taube, Christian ;

Oezkan, Filiz .

EUROPEAN JOURNAL OF CANCER, 2021, 147 :142-150

[74] Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges [J].

Seijo, Luis M. ;

Peled, Nir ;

Ajona, Daniel ;

Boeri, Mattia ;

Field, John K. ;

Sozzi, Gabriella ;

Pio, Ruben ;

Zulueta, Javier J. ;

Spira, Avrum ;

Massion, Pierre P. ;

Mazzone, Peter J. ;

Montuenga, Luis M. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (03) :343-357

[75] The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation [J].

Shivakumar, L ;

Minna, J ;

Sakamaki, T ;

Pestell, R ;

White, MA .

MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (12) :4309-4318

[76]

SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO

[77]

2-Q

[78] The probability of malignancy in solitary pulmonary nodules - Application to small radiologically indeterminate nodules [J].

Swensen, SJ ;

Silverstein, MD ;

Ilstrup, DM ;

Schleck, CD ;

Edell, ES .

ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (08) :849-855

[79] The multi-omic landscape of transcription factor inactivation in cancer [J].

Teschendorff, Andrew E. ;

Zheng, Shijie C. ;

Feber, Andy ;

Yang, Zhen ;

Beck, Stephan ;

Widschwendter, Martin .

GENOME MEDICINE, 2016, 8

[80]

Toyooka S, 2003, CLIN CANCER RES, V9, P3034

← 1 2 3 4 5 6 7 8 9 10 →